ES2970198T3 - Isoforma VTFT de una proteína BPIFB4 para uso en enfermedades y lesiones neuronales - Google Patents

Isoforma VTFT de una proteína BPIFB4 para uso en enfermedades y lesiones neuronales Download PDF

Info

Publication number
ES2970198T3
ES2970198T3 ES18756412T ES18756412T ES2970198T3 ES 2970198 T3 ES2970198 T3 ES 2970198T3 ES 18756412 T ES18756412 T ES 18756412T ES 18756412 T ES18756412 T ES 18756412T ES 2970198 T3 ES2970198 T3 ES 2970198T3
Authority
ES
Spain
Prior art keywords
protein
vector
disease
vtft
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18756412T
Other languages
English (en)
Spanish (es)
Inventor
Annibale Alessandro Puca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lgv1 Srl
Original Assignee
Lgv1 Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lgv1 Srl filed Critical Lgv1 Srl
Application granted granted Critical
Publication of ES2970198T3 publication Critical patent/ES2970198T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES18756412T 2017-08-16 2018-08-16 Isoforma VTFT de una proteína BPIFB4 para uso en enfermedades y lesiones neuronales Active ES2970198T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17186528 2017-08-16
PCT/EP2018/072184 WO2019034723A1 (en) 2017-08-16 2018-08-16 VTFT ISOFORM OF BPIFB4 PROTEIN INTENDED FOR USE IN NEURONAL DISEASES AND INJURIES

Publications (1)

Publication Number Publication Date
ES2970198T3 true ES2970198T3 (es) 2024-05-27

Family

ID=59713793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18756412T Active ES2970198T3 (es) 2017-08-16 2018-08-16 Isoforma VTFT de una proteína BPIFB4 para uso en enfermedades y lesiones neuronales

Country Status (8)

Country Link
US (1) US12311009B2 (https=)
EP (1) EP3668891B1 (https=)
JP (1) JP2020531047A (https=)
CN (1) CN111094327A (https=)
AU (1) AU2018317807A1 (https=)
CA (1) CA3109159A1 (https=)
ES (1) ES2970198T3 (https=)
WO (1) WO2019034723A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
AU2144999A (en) * 1998-01-13 1999-08-02 Claude Gravel Viral vectors encoding neurofilament heavy proteins and their use
WO1999036560A2 (en) * 1998-01-13 1999-07-22 Julien Jean Pierre Viral vectors encoding neurofilament light proteins and their use
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
AU2002313992B2 (en) * 1998-08-31 2006-09-21 Pro-Neuron, Inc. Compositions and Methods for Treatment of Mitochondrial Diseases
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6924357B2 (en) * 2000-04-18 2005-08-02 Merck Patent Gmbh Lipid binding protein 4
US6515197B1 (en) * 2000-08-24 2003-02-04 Cedars-Sinai Medical Center Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
JP2004532006A (ja) * 2001-02-08 2004-10-21 インサイト・ゲノミックス・インコーポレイテッド 細胞内シグナル伝達分子
WO2002090504A2 (en) * 2001-05-03 2002-11-14 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2003004660A1 (en) * 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
AU2002359284A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
NZ533833A (en) * 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
US20040092715A1 (en) * 2002-02-07 2004-05-13 Li Ding Intracellular signaling molecules
EP1489423A1 (en) * 2003-06-20 2004-12-22 Universite Louis Pasteur Use of mitochondrial uncoupling proteins for diagnostic, prevention and treatment of diseases involving neuromuscular affection
WO2005095610A1 (en) * 2004-03-31 2005-10-13 Agt Biosciences Limited Nucleic acid expressed in the hypothalamus or muscle tissue and uses thereof in diagnoses
WO2006022619A2 (en) * 2004-07-22 2006-03-02 Sequenom, Inc. Methods for identifying risk of type ii diabetes and treatments thereof
CA2584986A1 (en) * 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
PL1879623T3 (pl) * 2005-05-02 2013-03-29 Genzyme Corp Terapia genowa zaburzeń rdzenia kręgowego
KR20080080109A (ko) * 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
PL2066791T3 (pl) * 2006-10-03 2013-02-28 Genzyme Corp Terapia Genowa do leczenia stwardnienia zanikowego bocznego i innych zaburzeń rdzenia kręgowego
EP2150117A4 (en) * 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
WO2009020624A1 (en) * 2007-08-08 2009-02-12 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Regulators of protein misfolding and neuroprotection and methods of use
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
WO2010071832A1 (en) 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
WO2010088729A1 (en) * 2009-02-04 2010-08-12 University Of Tasmania Through The Menzies Research Institute Compositions and uses therefor
JP5879256B2 (ja) * 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
CA2800375C (en) * 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
US20140147434A1 (en) * 2011-05-06 2014-05-29 Ecole Polytechnique Federale De Lausanne (Epfl) NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function
US10815285B2 (en) * 2011-07-01 2020-10-27 University Of South Florida Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
JP6253596B2 (ja) * 2012-02-16 2017-12-27 ザ ペン ステイト リサーチ ファンデーション アシル補酵素ａ：リゾカルジオリピン・アシル基転移酵素１（ａｌｃａｔ１）の発現、機能または活性の阻害物質を同定する方法
EP2895621B1 (en) * 2012-09-14 2020-10-21 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
EP2749569A1 (en) * 2012-12-28 2014-07-02 Annibale Alessandro Puca Variant of BPIFB4 protein
WO2014161095A1 (en) * 2013-04-04 2014-10-09 Crp40 Inc. Crp40 fragments for the treatment of neurological disorders
AU2014329606B2 (en) * 2013-10-01 2020-02-06 Dana-Farber Cancer Institute, Inc. Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using Fndc5
US20170129930A1 (en) * 2014-06-19 2017-05-11 Board Of Trustees Of The University Of Arkansas Compositions and methods for modulating neuronal degeneration
US11027024B2 (en) * 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
CA2973891A1 (en) * 2016-07-21 2018-01-21 Stealth Biotherapeutics Corp Therapeutic compositions including modified creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions

Also Published As

Publication number Publication date
JP2020531047A (ja) 2020-11-05
CN111094327A (zh) 2020-05-01
EP3668891A1 (en) 2020-06-24
US20210128681A1 (en) 2021-05-06
AU2018317807A1 (en) 2020-02-06
EP3668891B1 (en) 2023-07-26
US12311009B2 (en) 2025-05-27
WO2019034723A1 (en) 2019-02-21
EP3668891C0 (en) 2023-07-26
CA3109159A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US20240383956A1 (en) Methods and materials for nt-3 gene therapy
JP6397391B2 (ja) 神経変性障害のための遺伝子治療
JP5766389B2 (ja) 脊髄疾患の遺伝子療法
ES2978086T3 (es) Terapia génica con aspartoacilasa en el tratamiento de enfermedad de Canavan
CN110325219B (zh) 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
US20260062713A1 (en) Adeno-associated virus delivery of cln3 polynucleotide
ES2970198T3 (es) Isoforma VTFT de una proteína BPIFB4 para uso en enfermedades y lesiones neuronales
WO2017059554A1 (es) Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrófica
HK40031704A (en) Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
HK40031704B (en) Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
WO2022170038A1 (en) Adeno-associated virus delivery of cln3 polynucleotide
HK40121244A (zh) Nt-3基因疗法的方法和材料
CN119326898A (zh) 靶向星形胶质细胞修复脑内磷稳态的基因疗法
EA052396B1 (ru) Способы и материалы для направленной на nt-3 генной терапии